Deregulated Cdk5 Activity Is Involved in Inducing Alzheimer's Disease

Archives of Medical Research

Volumn 43, Issue 8, 2012, Pages 655-662

  Shukla, Varsha ^a   Skuntz, Susan ^a   Pant, Harish C ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Alzheimer's disease; Cyclin dependent kinase 5 (Cdk5); Hyperphosphorylation; Neurodegeneration; Plaques; Tangles

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CYCLIN DEPENDENT KINASE 5; NEUROFILAMENT PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; AMYLOID PLAQUE; CELL SURVIVAL; DISEASE ASSOCIATION; HUMAN; NERVE CELL DIFFERENTIATION; NERVE CELL PLASTICITY; NEUROFIBRILLARY TANGLE; NEUROTOXICITY; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; STRESS;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; CYCLIN-DEPENDENT KINASE 5; HUMANS; MOLECULAR TARGETED THERAPY; NERVE DEGENERATION; NEUROFIBRILLARY TANGLES; PHOSPHORYLATION; PLAQUE, AMYLOID; TAU PROTEINS;

EID: 84871649258     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2012.10.015     Document Type: Review

References (96)

1. Sternberger N.H., Sternberger L.A., Ulrich J. Aberrant neurofilament phosphorylation in Alzheimer disease. Proc Natl Acad Sci USA 1985, 82:4274-4276.
2. Cork L.C., Sternberger N.H., Sternberger L.A., et al. Phosphorylated neurofilament antigens in neurofibrillary tangles in Alzheimer's disease. J Neuropathol Exp Neurol 1986, 45:56-64.
3. Lee K.Y., Clark A.W., Rosales J.L., et al. Elevated neuronal Cdc2-like kinase activity in the Alzheimer disease brain. Neurosci Res 1999, 34:21-29.
4. Patrick G.N., Zukerberg L., Nikolic M., et al. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 1999, 402:615-622.
5. Meyerson M., Enders G.H., Wu C.L., et al. A family of human cdc2-related protein kinases. EMBO J 1992, 11:2909-2917.
6. Hellmich M.R., Pant H.C., Wada E., et al. Neuronal cdc2-like kinase: a cdc2-related protein kinase with predominantly neuronal expression. Proc Natl Acad Sci USA 1992, 89:10867-10871.
7. Ohshima T., Ward J.M., Huh C.G., et al. Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. Proc Natl Acad Sci USA 1996, 93:11173-11178.
8. Nikolic M., Dudek H., Kwon Y.T., et al. The cdk5/p35 kinase is essential for neurite outgrowth during neuronal differentiation. Genes Dev 1996, 10:816-825.
9. Tan T.C., Valova V.A., Malladi C.S., et al. Cdk5 is essential for synaptic vesicle endocytosis. Nat Cell Biol 2003, 5:701-710.
10. Fischer A., Sananbenesi F., Schrick C., et al. Cyclin-dependent kinase 5 is required for associative learning. J Neurosci 2002, 22:3700-3707.
11. Noble W., Olm V., Takata K., et al. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 2003, 38:555-565.
12. Lee M.S., Kwon Y.T., Li M., et al. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 2000, 405:360-364.
13. Ahlijanian M.K., Barrezueta N.X., Williams R.D., et al. Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc Natl Acad Sci USA 2000, 97:2910-2915.
14. O'Brien R.J., Wong P.C. Amyloid precursor protein processing and Alzheimer's disease. Annu Rev Neurosci 2011, 34:185-204.
15. Selkoe D.J., Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 2003, 43:545-584.
16. Selkoe D.J. Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis 2001, 3:75-80.
17. Tanzi R.E., Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 2005, 120:545-555.
18. Maarouf C.L., Daugs I.D., Spina S., et al. Histopathological and molecular heterogeneity among individuals with dementia associated with presenilin mutations. Mol Neurodegener 2008, 3:20.
19. Shen J., Kelleher R.J. The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism. Proc Natl Acad Sci USA 2007, 104:403-409.
20. Yankner B.A., Dawes L.R., Fisher S., et al. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science 1989, 245:417-420.
21. Zheng Y.L., Li B.S., Amin N.D., et al. A peptide derived from cyclin-dependent kinase activator (p35) specifically inhibits Cdk5 activity and phosphorylation of tau protein in transfected cells. Eur J Biochem 2002, 269:4427-4434.
22. Deshpande A., Mina E., Glabe C., et al. Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J Neurosci 2006, 26:6011-6018.
23. Oakley H., Cole S.L., Logan S., et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci 2006, 26:10129-10140.
24. Kamenetz F., Tomita T., Hsieh H., et al. APP processing and synaptic function. Neuron 2003, 37:925-937.
25. Shankar G.M., Li S., Mehta T.H., et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008, 14:837-842.
26. Chen G., Chen K.S., Knox J., et al. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature 2000, 408:975-979.
27. El Khoury J., Toft M., Hickman S.E., et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med 2007, 13:432-438.
28. Halawani D., Tessier S., Anzellotti D., et al. Identification of caspase-6-mediated processing of the valosin containing protein (p97) in Alzheimer's disease: a novel link to dysfunction in ubiquitin proteasome system-mediated protein degradation. J Neurosci 2010, 30:6132-6142.
29. Rohn T.T., Head E. Caspases as therapeutic targets in Alzheimer's disease: is it time to "cut" to the chase?. Int J Clin Exp Pathol 2009, 2:108-118.
30. Shaw L.M., Vanderstichele H., Knapik-Czajka M., et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009, 65:403-413.
31. Steinerman J.R., Irizarry M., Scarmeas N., et al. Distinct pools of beta-amyloid in Alzheimer disease-affected brain: a clinicopathologic study. Arch Neurol 2008, 65:906-912.
32. Donmez G., Wang D., Cohen D.E., et al. SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10. Cell 2010, 142:320-332.
33. Holsinger R.M., McLean C.A., Beyreuther K., et al. Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann Neurol 2002, 51:783-786.
34. Yang L.B., Lindholm K., Yan R., et al. Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med 2003, 9:3-4.
35. Yuede C.M., Zimmerman S.D., Dong H., et al. Effects of voluntary and forced exercise on plaque deposition, hippocampal volume, and behavior in the Tg2576 mouse model of Alzheimer's disease. Neurobiol Dis 2009, 35:426-432.
36. Rovio S., Kareholt I., Helkala E.L., et al. Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease. Lancet Neurol 2005, 4:705-711.
37. Verghese J., LeValley A., Derby C., et al. Leisure activities and the risk of amnestic mild cognitive impairment in the elderly. Neurology 2006, 66:821-827.
38. Goedert M., Wischik C.M., Crowther R.A., et al. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc Natl Acad Sci USA 1988, 85:4051-4055.
39. Khlistunova I., Biernat J., Wang Y., et al. Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. J Biol Chem 2006, 281:1205-1214.
40. Santacruz K., Lewis J., Spires T., et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005, 309:476-481.
41. Oddo S., Vasilevko V., Caccamo A., et al. Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem 2006, 281:39413-39423.
42. Lee V.M., Goedert M., Trojanowski J.Q. Neurodegenerative tauopathies. Annu Rev Neurosci 2001, 24:1121-1159.
43. Hanger D.P., Betts J.C., Loviny T.L., et al. New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J Neurochem 1998, 71:2465-2476.
44. Keck S., Nitsch R., Grune T., et al. Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease. J Neurochem 2003, 85:115-122.
45. Smith M.A. Alzheimer disease. Int Rev Neurobiol 1998, 42:1-54.
46. Cras P., Smith M.A., Richey P.L., et al. Extracellular neurofibrillary tangles reflect neuronal loss and provide further evidence of extensive protein cross-linking in Alzheimer disease. Acta Neuropathol 1995, 89:291-295.
47. Iqbal K., Alonso Adel C., Chen S., et al. Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 2005, 1739:198-210.
48. Iqbal K., Zaidi T., Bancher C., et al. Alzheimer paired helical filaments. Restoration of the biological activity by dephosphorylation. FEBS Lett 1994, 349:104-108.
49. Stoothoff W.H., Johnson G.V. Tau phosphorylation: physiological and pathological consequences. Biochim Biophys Acta 2005, 1739:280-297.
50. Rudrabhatla P., Grant P., Jaffe H., et al. Quantitative phosphoproteomic analysis of neuronal intermediate filament proteins (NF-M/H) in Alzheimer's disease by iTRAQ. FASEB J 2010, 24:4396-4407.
51. Shetty K.T., Link W.T., Pant H.C. cdc2-like kinase from rat spinal cord specifically phosphorylates KSPXK motifs in neurofilament proteins: isolation and characterization. Proc Natl Acad Sci USA 1993, 90:6844-6848.
52. Nukina N., Kosik K.S., Selkoe D.J. Recognition of Alzheimer paired helical filaments by monoclonal neurofilament antibodies is due to crossreaction with tau protein. Proc Natl Acad Sci USA 1987, 84:3415-3419.
53. Dhavan R., Tsai L.H. A decade of CDK5. Nat Rev Mol Cell Biol 2001, 2:749-759.
54. Amin N.D., Albers W., Pant H.C. Cyclin-dependent kinase 5 (cdk5) activation requires interaction with three domains of p35. J Neurosci Res 2002, 67:354-362.
55. Tsai L.H., Delalle I., Caviness V.S., et al. p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature 1994, 371:419-423.
56. Ko J., Humbert S., Bronson R.T., et al. p35 and p39 are essential for cyclin-dependent kinase 5 function during neurodevelopment. J Neurosci 2001, 21:6758-6771.
57. Patrick G.N., Zhou P., Kwon Y.T., et al. p35, the neuronal-specific activator of cyclin-dependent kinase 5 (Cdk5) is degraded by the ubiquitin-proteasome pathway. J Biol Chem 1998, 273:24057-24064.
58. Tang D., Chun A.C., Zhang M., et al. Cyclin-dependent kinase 5 (Cdk5) activation domain of neuronal Cdk5 activator. Evidence of the existence of cyclin fold in neuronal Cdk5a activator. J Biol Chem 1997, 272:12318-12327.
59. Chang K.H., Multani P.S., Sun K.H., et al. Nuclear envelope dispersion triggered by deregulated Cdk5 precedes neuronal death. Mol. Biol. Cell 2011, 22:1452-1462.
60. Cruz J.C., Tsai L.H. Cdk5 deregulation in the pathogenesis of Alzheimer's disease. Trends Mol Med 2004, 10:452-458.
61. Quintanilla R.A., Orellana D.I., Gonzalez-Billault C., et al. Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. Exp Cell Res 2004, 295:245-257.
62. Sun K.H., de Pablo Y., Vincent F., et al. Deregulated Cdk5 promotes oxidative stress and mitochondrial dysfunction. J Neurochem 2008, 107:265-278.
63. Shea T.B., Zheng Y.L., Ortiz D., et al. Cyclin-dependent kinase 5 increases perikaryal neurofilament phosphorylation and inhibits neurofilament axonal transport in response to oxidative stress. J Neurosci Res 2004, 76:795-800.
64. Chang K.-H., de Pablo Y., Lee H.P., et al. Cdk5 is a major regulator of p38 cascade: relevance to neurotoxicity in Alzheimer's disease. J Neurochem 2010, 113:1221-1229.
65. Pei J.J., Braak E., Braak H., et al. Localization of active forms of C-jun kinase (JNK) and p38 kinase in Alzheimer's disease brains at different stages of neurofibrillary degeneration. J Alzheimers Dis 2001, 3:41-48.
66. Zhu X., Rottkamp C.A., Hartzler A., et al. Activation of MKK6, an upstream activator of p38, in Alzheimer's disease. J Neurochem 2001, 79:311-318.
67. Nguyen M.D., Lariviere R.C., Julien J.P. Deregulation of Cdk5 in a mouse model of ALS: toxicity alleviated by perikaryal neurofilament inclusions. Neuron 2001, 30:135-147.
68. Alvira D., Ferrer I., Gutierrez-Cuesta J., et al. Activation of the calpain/cdk5/p25 pathway in the girus cinguli in Parkinson's disease. Parkinsonism Relat Disord 2008, 14:309-313.
69. Avraham E., Rott R., Liani E., et al. Phosphorylation of Parkin by the cyclin-dependent kinase 5 at the linker region modulates its ubiquitin-ligase activity and aggregation. J Biol Chem 2007, 282:12842-12850.
70. Shukla V., Mishra S.K., Pant H.C. Oxidative stress in neurodegeneration. Adv Pharmacol Sci 2011, 2011:572634.
71. Selkoe D.J. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 1999, 399(6738 suppl):A23-A31.
72. Kesavapany S., Zheng Y.L., Amin N., et al. Peptides derived from Cdk5 activator p35, specifically inhibit deregulated activity of Cdk5. Biotechnol J 2007, 2:978-987.
73. Zheng Y.L., Kesavapany S., Gravell M., et al. A Cdk5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons. EMBO J 2005, 24:209-220.
74. Iijima K., Ando K., Takeda S., et al. Neuron-specific phosphorylation of Alzheimer's beta-amyloid precursor protein by cyclin-dependent kinase 5. J Neurochem 2000, 75:1085-1091.
75. Ando K., Iijima K.I., Elliott J.I., et al. Phosphorylation-dependent regulation of the interaction of amyloid precursor protein with Fe65 affects the production of beta-amyloid. J Biol Chem 2001, 276:40353-40361.
76. Lee M.S., Kao S.C., Lemere C.A., et al. APP processing is regulated by cytoplasmic phosphorylation. J Cell Biol 2003, 163:83-95.
77. Cruz J.C., Tseng H.C., Goldman J.A., et al. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 2003, 40:471-483.
78. Sobue K., Agarwal-Mawal A., Li W., et al. Interaction of neuronal Cdc2-like protein kinase with microtubule-associated protein tau. J Biol Chem 2000, 275:16673-16680.
79. Flaherty D.B., Soria J.P., Tomasiewicz H.G., et al. Phosphorylation of human tau protein by microtubule-associated kinases: GSK3beta and cdk5 are key participants. J Neurosci Res 2000, 62:463-472.
80. Ishiguro K., Sato K., Takamatsu M., et al. Analysis of phosphorylation of tau with antibodies specific for phosphorylation sites. Neurosci Lett 1995, 202:81-84.
81. Lund E.T., McKenna R., Evans D.B., et al. Characterization of the in vitro phosphorylation of human tau by tau protein kinase II (cdk5/p20) using mass spectrometry. J Neurochem 2001, 76:1221-1232.
82. Yamaguchi H., Ishiguro K., Uchida T., et al. Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathol 1996, 92:232-241.
83. Liu W.K., Williams R.T., Hall F.L., et al. Detection of a Cdc2-related kinase associated with Alzheimer paired helical filaments. Am J Pathol 1995, 146:228-238.
84. Pei J.J., Grundke-Iqbal I., Iqbal K., et al. Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration. Brain Res 1998, 797:267-277.
85. Augustinack J.C., Sanders J.L., Tsai L.H., et al. Colocalization and fluorescence resonance energy transfer between cdk5 and AT8 suggests a close association in pre-neurofibrillary tangles and neurofibrillary tangles. J Neuropathol Exp Neurol 2002, 61:557-564.
86. Hashiguchi M., Saito T., Hisanaga S., et al. Truncation of CDK5 activator p35 induces intensive phosphorylation of Ser202/Thr205 of human tau. J Biol Chem 2002, 277:44525-44530.
87. Yen S.H., Gaskin F., Fu S.M. Neurofibrillary tangles in senile dementia of the Alzheimer type share an antigenic determinant with intermediate filaments of the vimentin class. Am J Pathol 1983, 113:373-381.
88. Rudrabhatla P., Jaffe H., Pant H.C. Direct evidence of phosphorylated neuronal intermediate filament proteins in neurofibrillary tangles (NFTs): phosphoproteomics of Alzheimer's NFTs. FASEB J 2011, 25:3896-3905.
89. Zhou J., Wang H., Feng Y., Chen J. Increased expression of cdk5/p25 in N2a cells leads to hyperphosphorylation and impaired axonal transport of neurofilament proteins. Life Sci 2010, 86:532-537.
90. Shah R.S., Lee H.G., Xiongwei Z., et al. Current approaches in the treatment of Alzheimer's disease. Biomed Pharmacother 2008, 62:199-207.
91. Bard F., Cannon C., Barbour R., et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000, 6:916-919.
92. Maier M., Seabrook T.J., Lazo N.D., et al. Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. J Neurosci 2006, 26:4717-4728.
93. Piedrahita D., Hernandez I., Lopez-Tobon A., et al. Silencing of CDK5 reduces neurofibrillary tangles in transgenic Alzheimer's mice. J Neurosci 2010, 30:13966-13976.
94. Helal C.J., Sanner M.A., Cooper C.B., et al. Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer's disease. Bioorg Med Chem Lett 2004, 14:5521-5525.
95. Helal C.J., Kang Z., Lucas J.C., et al. Potent and cellularly active 4-aminoimidazole inhibitors of cyclin-dependent kinase 5/p25 for the treatment of Alzheimer's disease. Bioorg Med Chem Lett 2009, 19:5703-5707.
96. Knockaert M., Wieking K., Schmitt S., et al. Intracellular targets of paullones. Identification following affinity purification on immobilized inhibitor. J Biol Chem 2002, 277:25493-25501.